These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23648467)

  • 1. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
    Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
    Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
    Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involved-field radiation therapy for selected cases of recurrent ovarian cancer.
    Kim N; Chang JS; Kim SW; Kim GM; Lee JY; Kim YB
    J Gynecol Oncol; 2019 Sep; 30(5):e67. PubMed ID: 31328453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer.
    Machida S; Takei Y; Yoshida C; Takahashi Y; Koyanagi T; Sato N; Taneichi A; Saga Y; Fujiwara H; Suzuki M
    Oncology; 2014; 86(4):232-8. PubMed ID: 24853194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.
    Albuquerque KV; Singla R; Potkul RK; Smith DM; Creech S; Lo S; Emami B
    Gynecol Oncol; 2005 Mar; 96(3):701-4. PubMed ID: 15721414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer.
    Albuquerque K; Patel M; Liotta M; Harkenrider M; Guo R; Small W; Ronald P
    Int J Gynecol Cancer; 2016 May; 26(4):655-60. PubMed ID: 26825832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Jansaka N; Suprasert P
    Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of long-term survivors of recurrent epithelial ovarian cancer.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Sakamoto K; Takizawa K; Takeshima N
    Int J Clin Oncol; 2015 Feb; 20(1):143-9. PubMed ID: 24664306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel B; Buss MK; Nattam S; Hurteau J; Luo W; Quy P; Whalen C; Obermayer L; Lee H; Winer EP; Kohn EC; Ivy SP; Matulonis UA
    Lancet Oncol; 2014 Oct; 15(11):1207-14. PubMed ID: 25218906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study.
    Gao Y; Liu Z; Chen X; Luo W; Zhang L; Wang J
    BMC Cancer; 2011 Oct; 11():439. PubMed ID: 21989202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
    Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
    Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.